Condition: Breast Cancer · Gastric Cancer · Gastroesophageal-junction Cancer · Sponsor: Iksuda Therapeutics Ltd.
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
David Browning · +1-615-975-7776 · david.browning@iksuda.com
Always discuss trial participation with your own doctor first.
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
| START Dallas - Fort Worth | Fort Worth, Texas, United States | Recruiting |
| Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit | Concord, New South Wales, Australia | Recruiting |
| Macquarie University | Sydney, New South Wales, Australia | Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| Peninsula & South Eastern Haematology and Oncology Group (PSEHOG) | Frankston, Victoria, Australia | Recruiting |
| Alfred Health | Melbourne, Victoria, Australia | Recruiting |
| Linear Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
| Auckland City Hospital | Auckland, New Zealand | Recruiting |
| National Cancer Centre Singapore | Singapore, Singapore | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05872295